An Amyloid/Tau/Neurodegeneration-Clinical Dementia Rating (ATN-CDR) mode was used in this study to evaluate the natural progression process of Alzheimer's dementia, which offers a comprehensive and reasonable way of taking both pathological and clinical presentations into account (14). The gene discussed is MAPT; the disease is Alzheimer disease.